How the answers frame Johnson & Johnson
This snapshot, measured on 2026-09-28, covers 25 answers to four category questions that never named a brand. Johnson & Johnson was named in 13 of them, across the trust, pricing, patient-access and litigation questions. By assistant it appeared in answers from ChatGPT, Gemini, Perplexity and Grok, and in none from Claude.
On trust, the answers were cautious. Most said there is no single ranking of the most trusted drugmakers. Perplexity and Grok still listed Johnson & Johnson among the stronger reputation performers, and Gemini included it in a group noted for reputation. ChatGPT named it in an answer that mostly said pharma is not highly trusted as an industry.
On patient access, the answers leaned on the 2024 Access to Medicine Index. ChatGPT and Grok listed Johnson & Johnson tied for fifth. Perplexity instead relayed the company's own description of a #2 ranking. Same index, two different placements.
On litigation and pricing, the framing turned. ChatGPT called it "a major defendant in opioid litigation and also one of the largest pharma penalty/settlement names." Perplexity cited talc claims and lawsuit counts. Gemini and Grok put it in the group of large drugmakers criticized on pricing, and Gemini also described congressional testimony and U.S.-versus-abroad price gaps.
The credit categories reflect this split. The most common was "Not Substantive" (5 answers), followed by Safety & Compliance (4), Price & Value (2) and Sustainability & Ethics (1). In these answers the company is a name in every list, but the reason it is named varies with the question.
…a major defendant in opioid litigation and also one of the largest pharma penalty/settlement names.
What the press is saying
PeakMetrics' news index shows 15,149 mentions of Johnson & Johnson over the last 30 days, with the company in the headline of 1,965 of them. In this sector snapshot that is comparable to Pfizer (18,663) and Merck (20,326).
The five recent headlines supplied are about markets and money: an institutional holding in $JNJ, a wealth advisor buying shares, a stock price move on insider selling, a healthcare equipment market report listing the company, and a procurement contract award. These headlines are a small sample, and none of them is about trust, access, pricing or litigation.
…appears in the top tier in several reputation/trust lists, including patient-group and public reputation-oriented rankings.
The gap
The answers describe Johnson & Johnson through reputation surveys, access rankings, settlements and lawsuit counts. The headlines supplied describe it through share purchases, price moves and market reports. Only the AI answers speak to the questions about how the company is regarded and what it has been sued over.
Press volume also does not map neatly onto how often the assistants named the company. Eli Lilly has 19,280 news mentions and appeared in 6 of 25 answers. Johnson & Johnson has 15,149 and appeared in 13. Coverage volume and AI visibility are separate measures.
…highlights its #2 ranking on the Access to Medicine Index, which it describes as reflecting a longstanding commitment to make medicines available and accessible.
What to watch
For a Johnson & Johnson comms team, the takeaway from this single snapshot is that the company is present in the category conversation, but the assistants attach it to different storylines depending on the question. The same company can appear as a reputation name, an access name and a litigation name within one measurement run.
Two things are worth checking in repeat runs. One is the access-index placement, where the answers disagreed (tied fifth in two answers, #2 in a third that relayed the company's own description). The other is the litigation answers, which lean on third-party compilations and analyses. Claude's absence in this run is also worth a look. Live answers vary between runs, so treat this as a snapshot, not a ranking.